[Praziquantel in the prevention of recurrence of human echinococcosis].
In a five year long study efficiency of Praziquental in a prevention of human echinococcosis relapses was studied. Study was conducted in a period from October 1996 till October 2000, and it included patients with echinoccosis treated in Clinical Center of Sarajevo University in Sarajevo, and in Hospital Konjic, in Konjic. In the above stated period 136 patients with echinoccosis were treated surgically, and in 30 of them combined therapy with Praziquental was used. Antihelmint therapy was applied in hospital settings for 14 days in a dose of 25-50 mg/kg of body weight with adjuvant corticotherapy. After hospital discharge patients were followed up in outpatient clinics by infectologists, surgeons and pediatricians. Follow up included clinical, biochemical, ultrasonic and radiological investigations. Longest follow up interval was 5.5 years and shortest year and a half. Results of study have shown that in a group of 106 patients, treated only with surgical treatment, there were 12.5% of relapses. In a group of patients that we treated with combined therapy with Praziquental there were not relapses. Our results suggest Praziquental could be a drug of choice for the prevention of relapses in human echinoccosis in a combined therapy.